Ginkgo Bioworks Holdings Stock Performance
| DNA Stock | USD 9.31 0.12 1.27% |
The company retains a Market Volatility (i.e., Beta) of 2.23, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ginkgo Bioworks will likely underperform. At this point, Ginkgo Bioworks Holdings has a negative expected return of -0.41%. Please make sure to check out Ginkgo Bioworks' maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if Ginkgo Bioworks Holdings performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Ginkgo Bioworks Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (1.27) | Five Day Return (13.15) | Year To Date Return 7.01 | Ten Year Return (97.70) | All Time Return (97.70) |
Last Split Factor 1:40 | Last Split Date 2024-08-20 |
1 | The DNA Company Named Functional Genomics Innovation of the Year for the 2025 BioTech Breakthrough Awards | 11/10/2025 |
2 | Will Ginkgo Bioworks Holdings Inc. stock recover faster than market - July 2025 Gainers Free Weekly Chart Analysis and Trade Guides - B NI V | 11/26/2025 |
3 | Disposition of 1061 shares by Mark Dmytruk of Ginkgo Bioworks subject to Rule 16b-3 | 11/28/2025 |
4 | Disposition of 1244 shares by Mark Dmytruk of Ginkgo Bioworks at 7.283 subject to Rule 16b-3 | 12/01/2025 |
5 | Disposition of 312 shares by Coen Steven P. of Ginkgo Bioworks subject to Rule 16b-3 | 12/12/2025 |
6 | Leonardo da Vinci DNA discovery could uncover lost paintings | 01/07/2026 |
7 | Ginkgo Bioworks Holdings, Inc. Stock Dips While Market Gains Key Facts | 01/08/2026 |
8 | DNA storage meets blockchain permanence in the enterprise era | 01/12/2026 |
9 | Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference | 01/13/2026 |
10 | Disrupting Biotech Jurek Kozyra Unveils DNA Nanorobots That Could Cure the Incurable | 01/15/2026 |
11 | Disposition of 587 shares by Coen Steven P. of Ginkgo Bioworks subject to Rule 16b-3 | 01/16/2026 |
12 | Ginkgo Bioworks Trading Down 8.8 percent Time to Sell | 01/20/2026 |
13 | High-tech DNA could ID cold-case Asian Doe Gilgo Beach victim DA | 01/21/2026 |
14 | Theanti-aging supplement Kim Kardashian andBryan Johnson have in common its more effective than NAD | 01/29/2026 |
| Begin Period Cash Flow | 989.6 M | |
| Total Cashflows From Investing Activities | -62.2 M |
Ginkgo Bioworks Relative Risk vs. Return Landscape
If you would invest 1,279 in Ginkgo Bioworks Holdings on November 1, 2025 and sell it today you would lose (348.00) from holding Ginkgo Bioworks Holdings or give up 27.21% of portfolio value over 90 days. Ginkgo Bioworks Holdings is generating negative expected returns assuming volatility of 4.733% on return distribution over 90 days investment horizon. In other words, 42% of stocks are less volatile than Ginkgo, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Ginkgo Bioworks Target Price Odds to finish over Current Price
The tendency of Ginkgo Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 9.31 | 90 days | 9.31 | about 54.18 |
Based on a normal probability distribution, the odds of Ginkgo Bioworks to move above the current price in 90 days from now is about 54.18 (This Ginkgo Bioworks Holdings probability density function shows the probability of Ginkgo Stock to fall within a particular range of prices over 90 days) .
Considering the 90-day investment horizon the stock has the beta coefficient of 2.23 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Ginkgo Bioworks will likely underperform. Additionally Ginkgo Bioworks Holdings has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Ginkgo Bioworks Price Density |
| Price |
Predictive Modules for Ginkgo Bioworks
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Ginkgo Bioworks Holdings. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Ginkgo Bioworks Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Ginkgo Bioworks is not an exception. The market had few large corrections towards the Ginkgo Bioworks' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Ginkgo Bioworks Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Ginkgo Bioworks within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.58 | |
β | Beta against Dow Jones | 2.23 | |
σ | Overall volatility | 1.43 | |
Ir | Information ratio | -0.11 |
Ginkgo Bioworks Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Ginkgo Bioworks for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Ginkgo Bioworks Holdings can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Ginkgo Bioworks generated a negative expected return over the last 90 days | |
| Ginkgo Bioworks has high historical volatility and very poor performance | |
| Ginkgo Bioworks has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 227.04 M. Reported Net Loss for the year was (547.03 M) with profit before taxes, overhead, and interest of 131.31 M. | |
| Ginkgo Bioworks Holdings has about 561.57 M in cash with (319.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.84. | |
| Roughly 70.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from nypost.com: Theanti-aging supplement Kim Kardashian andBryan Johnson have in common its more effective than NAD |
Ginkgo Bioworks Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Ginkgo Stock often depends not only on the future outlook of the current and potential Ginkgo Bioworks' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Ginkgo Bioworks' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 51.9 M | |
| Cash And Short Term Investments | 561.6 M |
Ginkgo Bioworks Fundamentals Growth
Ginkgo Stock prices reflect investors' perceptions of the future prospects and financial health of Ginkgo Bioworks, and Ginkgo Bioworks fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ginkgo Stock performance.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.88) % | ||||
| Operating Margin | (2.27) % | ||||
| Current Valuation | 525.1 M | ||||
| Shares Outstanding | 48.52 M | ||||
| Price To Earning | 25.51 X | ||||
| Price To Book | 1.02 X | ||||
| Price To Sales | 3.12 X | ||||
| Revenue | 227.04 M | ||||
| Gross Profit | 131.31 M | ||||
| EBITDA | (484.39 M) | ||||
| Net Income | (547.03 M) | ||||
| Cash And Equivalents | 561.57 M | ||||
| Cash Per Share | 0.84 X | ||||
| Total Debt | 467.73 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 11.84 X | ||||
| Book Value Per Share | 9.85 X | ||||
| Cash Flow From Operations | (319.58 M) | ||||
| Earnings Per Share | (6.18) X | ||||
| Market Capitalization | 564.09 M | ||||
| Total Asset | 1.38 B | ||||
| Retained Earnings | (5.84 B) | ||||
| Working Capital | 495.48 M | ||||
| Current Asset | 10.07 B | ||||
| Current Liabilities | 3.1 B | ||||
About Ginkgo Bioworks Performance
By analyzing Ginkgo Bioworks' fundamental ratios, stakeholders can gain valuable insights into Ginkgo Bioworks' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ginkgo Bioworks has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ginkgo Bioworks has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.36 | 0.34 | |
| Return On Tangible Assets | (0.48) | (0.51) | |
| Return On Capital Employed | (0.51) | (0.53) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (0.88) | (0.92) |
Things to note about Ginkgo Bioworks Holdings performance evaluation
Checking the ongoing alerts about Ginkgo Bioworks for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ginkgo Bioworks Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ginkgo Bioworks generated a negative expected return over the last 90 days | |
| Ginkgo Bioworks has high historical volatility and very poor performance | |
| Ginkgo Bioworks has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 227.04 M. Reported Net Loss for the year was (547.03 M) with profit before taxes, overhead, and interest of 131.31 M. | |
| Ginkgo Bioworks Holdings has about 561.57 M in cash with (319.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.84. | |
| Roughly 70.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from nypost.com: Theanti-aging supplement Kim Kardashian andBryan Johnson have in common its more effective than NAD |
- Analyzing Ginkgo Bioworks' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ginkgo Bioworks' stock is overvalued or undervalued compared to its peers.
- Examining Ginkgo Bioworks' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ginkgo Bioworks' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ginkgo Bioworks' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ginkgo Bioworks' stock. These opinions can provide insight into Ginkgo Bioworks' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ginkgo Stock analysis
When running Ginkgo Bioworks' price analysis, check to measure Ginkgo Bioworks' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ginkgo Bioworks is operating at the current time. Most of Ginkgo Bioworks' value examination focuses on studying past and present price action to predict the probability of Ginkgo Bioworks' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ginkgo Bioworks' price. Additionally, you may evaluate how the addition of Ginkgo Bioworks to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |